Clinical trial
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma
NCT02836548 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma
- Lead sponsor
- The Netherlands Cancer Institute
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- June 30, 2016
- Completion date
- November 30, 2023
- Enrollment
- 33 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.